Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Thumbnail
View/Open
Date
2022-01-01
Author
YASİN, Ayşe İrem
Aydin, Sabin Goktas
SÜMBÜL, BİLGE
KORAL, LOKMAN
ŞİMŞEK, MELİH
Geredeli, Caglayan
Ozturk, Akin
Perkin, Perihan
Demirtas, Derya
Erdemoglu, Engin
HACIBEKİROĞLU, İLHAN
Cakir, Emre
Tanrikulu, Eda
Coban, Ezgi
Ozcelik, Melike
Celik, Sinemis
Teker, Fatih
AKSOY, ASUDE
Firat, Sedat T.
Tekin, Omer
Kalkan, Ziya
Turken, Orhan
Oven, Bala B.
Dane, Faysal
Bilici, Ahmet
Isikdogan, Abdurrahman
ŞEKER, Mesut
TÜRK, HACI MEHMET
Gumus, Mahmut
Advisor
Type
Metadata
Show full item record
Abstract
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov)
Subject
URI
http://hdl.handle.net/20.500.12645/30384
Collections